MT7117 Study - Wesley Research Institute

This study is testing a potential new treatment for EPP or XLP that increases melanin in the skin, which protects you from sunlight.

Research Objectives

Status

Current

Recruitment

Closed

Study location

Wesley Research Institute

Study type

Industry Sponsored

Patient group

Indication: Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Industry sponsor

Mitsubishi Tanabe Pharma Development

About this clinical trial

Erythropoietic Protoporphyria (referred to as “EPP”) or X-Linked Protoporphyria (referred to as “XLP”) are characterized by the accumulation of a molecule named protoporphyrin in the body, which leads to pain when the skin is exposed to sunlight. The purpose of this trial is to investigate whether an experimental drug called MT-7117 (Dersimelagon) is effective and well tolerated in reducing the severity of symptoms of EPP or XLP.

  Lead investigator  
          Prof David Coman      

  Clinical trial coordinator  
          Venita Bali      

Technical title

A Phase 3, Multicenter, Open-Label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)